The future investment stars are already with us. The NYSE Financial Future Challenge, operated by the NYSE Foundation, By Kids for Kids, K12 Inc. and the United Investors Association, is in full swing, with five finalists just identified. To reach this level, the participants had to develop a new product, idea or process that would "excite, educate and motivate their peers" to become interested in the financial marketplace. The eventual winner lurks within this subset and will receive a $2,500 prize -- a great way to get that portfolio started. And, he or she will be feted at a closing bell ceremony at the NYSE (NYX) on January 11, 2010.

The finalists presented a variety of ideas which are sure to generate some buzz. Kelsey Foss, a 12-year-old from Mountainville, NY, proposed a new television show, "Stock Market Tycoon Idol," which would harness the popularity of reality TV while amping up the content. The program would involve the journeys of 10 kids as they seek to make money or lose it, with the possibility of becoming virtual millionaires along the way. The show would be set at a mock NYSE studio on Wall Street, and exports would be brought out to mentor the contestants. The reality TV reach would help engage a younger audience.

3M (NYSE: MMM) is one of those solid stocks that investors love to sock away in a core portfolio. It was down when pessimism about the economy was at its peak, but it's coming back now that Wall Street is becoming comfortable with the idea that the economic clouds will eventually give way to rays of macro sunshine.

Earlier in the week, 3M reported a great quarter. No, it wasn't so great on a comparable basis. The company, which counts Johnson & Johnson (NYSE: JNJ) and DuPont (NYSE: DD) as colleagues, suffered a decline of almost 6% on the top line in Q3. Earnings per share on an adjusted basis, which came in at $1.37 per share, were down 3.5%.

Kimberly-Clark Corporation (NYSE: KMB), a consumer products entity whose colleagues include Procter & Gamble (NYSE: PG) and Johnson & Johnson (NYSE: JNJ), is up today on third-quarter results. At the time of this writing, my screen was showing shares of Kimberly-Clark higher by a little under 6%.

According to the corporate press release, sales declined 1.7%. Not a great start, but Kimberly-Clark highlighted a better metric: organic sales increased 3%, helped along by price increases. Luckily, sales volume didn't fare too badly; they were essentially flat.

Since the stock market bottomed in March of this year, it has been firing on all cylinders -- except for those in the auto industry who manufacture the most cylinders of course. This year has not been kind to them.

For months, many have been surprised at the rapid rise, given the level of unemployment. During this same period, Wall Streeters have been dancing up and down, looking forward to more bonuses.

As the number of unemployed has climbed and the period of same has lengthened, many have wondered how business could be improving during a time when the consumer (those still left) has transformed from spender to saver.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Abbott Laboratories (NYSE: ABT) higher Q3 earnings topped expectations but revenue was in line.
• Advanced Micro Devices Inc. (NYSE: AMD) posted better-than-expected Q3 results, but shares sold off.
• Allegheny Technologies Inc. (NYSE: ATI) was downgraded on concerns about its Q4 guidance.
• Bank of America Corp. (NYSE: BAC) shares fell after it posted a deeper-than-expected quarterly loss.
• Citigroup Inc. (NYSE: C) fell victim to profit taking despite reporting better-than-expected earnings.
• CSX Corp. (NYSE: CSX) better-than-expected Q3 earnings sent shares higher, despite a decline in revenue.

Johnson & Johnson (NYSE: JNJ) reported its third quarter figures this morning, and while the company managed to post better than expected earnings, its revenues were lower than analysts had expected.

Going into this morning's earnings report analysts had estimated J&J would earn $1.13 per share in the third quarter. The company was able to put up better than expected earnings results, saying it earned $1.20 per share in the quarter. But revenues disappointed. Analysts had forecast the company's revenues would be $15.22 billion in the quarter, but actual revenues were below estimates at $15.08 billion.

Johnson & Johnson (NYSE: JNJ), the New Jersey-based health care giant, is scheduled to hold an analyst meeting to discuss its third quarter 2009 financial results Tuesday at 8:30 AM ET, hosted by CFO Dominic Caruso and others. You can catch the live broadcast of the meeting on the company's website.

During the three months that ended in September, Johnson & Johnson completed a biotech acquistion and announced a collaboration to combat the flu. Analysts surveyed by Thomson Reuters expect this dividend-paying company to report that net income fell three cents per share from a year ago to $1.13. Revenue for the period is expected to be 4.6% lower to $15.2 billion.

I'm reiterating my Buy rating for Johnson & Johnson (NYSE: JNJ), first recommended on May 20, 2009 at a price of $55.87.

The value proposition with Johnson & Johnson 'isn't rocket science', as they say, even though the business model does involve a considerable amount of science.

Medtronic (NYSE: MDT), a manufacturer of a whole host of medical devices involved with the management of diabetes and cardiovascular disease, released its Q1 data on Tuesday. Revenues increased 6%, and adjusted earnings per share came in at 79 cents (some of the adjustments were related to restructuring and litigation issues).

The company was able to grow the adjusted-per-share bottom line by 10%. In addition, according to Reuters, Medtronic beat estimates by a penny. Shareholders should keep in mind, however, that the quarter benefited from an extra week.

Money market accounts and certificates of deposit are safe, but they provide very little return on your investment. This fact, and the invigorated stock market, provoked one of my bankers, Dobrinka, at the local Santa Monica Wells Fargo branch, to ask for advice on how I would invest $25,000 if I was just starting out.

This is a common question although the starting point in terms of cash varies. It certainly makes a difference how old the person is, their general knowledge about investing and finance, and the particulars of their financial statement.

Here is what I suggested sticking to regular themes I have written about before and broadly speaking would be a conservative approach emphasizing safety, diversity, liquidity, dividends and the potential for growth far exceeding cash in the mattress or in a money market account. I also think that it is important for beginners to educate themselves so my suggestions include an educational aspect.

Facebook is making the biggest ad splash since Google, according to an article in the Financial Times.

More than four-fifths of the largest advertisers in the United States have turned to the social networking platform to promote their wares -- after several years of fearing these types of communities. The lure of Facebook must have been too much to resist, with 340 million monthly unique visitors. Now, it's not unusual to see the likes of Johnson & Johnson (NYSE: JNJ), Nike (NYSE: NKE), and AT&T (NYSE: ATT) advertising in this world.

Pharmaceutical company Merck (NYSE: MRK), whose colleagues include Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), issued its Q2 numbers earlier in the week. Quite frankly, I found them to be boring. Of course, maybe boring isn't too bad these days, right? It's a lot better than an exciting ride on a profit-decline express.

Well, actually, Merck did see a decline in its bottom-line profit, but it wasn't an outrageously awful drop or anything like that. Merck made an adjusted 83 cents per share compared to an adjusted 86 cents per share in the comparable period. Three less pennies isn't the worst thing in the world on a relative basis. Plus, revenues increased 3% if you exclude currency effects (including them gives a decrease of 3%).

Boston Scientific (NYSE: BSX), an expert in medical devices and a colleague of Johnson & Johnson (NYSE: JNJ), reported earnings for the second quarter on Monday after the closing bell. Wall Street liked the results. Shares of the company were bid higher by 5.8% in the after-hours session.

Net sales increased 7%. On an adjusted basis, Boston Scientific made 20 cents per share. According to Earnings.com, the business was supposed to bring in only 13 cents per share. Thus, management did a superb job of beating the analysts at their precious game. Unfortunately, Boston Scientific made the same amount of adjusted profit in the year-ago period, so there wasn't any growth on the bottom line.

Johnson & Johnson (NYSE: JNJ), a company that counts Procter & Gamble (NYSE: PG) and Pfizer (NYSE: PFE) as colleagues, will report results for the second quarter on Tuesday, July 14. JNJ is expected to post a bit of a profit decline. Last year's Q2, according to Earnings.com, saw the health-care business earn $1.18 per share. This time around, analysts are thinking that JNJ will do somewhere around $1.11 per share.

Will JNJ beat the analysts? It's quite possible, since the company has a good record on this count. As a matter of fact, JNJ beat predictions by four cents back in April. Sales, however, came in a little weak. Interestingly enough, the market didn't really care too much about the earnings performance on that day. Shares had rallied a bit in pre-market trading, but they closed slightly down by the end of the regular session. I found a similar situation back in January.

Billions of investment dollars are sitting on the sidelines for fear of entering the market at the wrong time and losing more money after taking a bath last year. However, the market seems to have hit bottom last March and many investors missed the 40% gain from that point to now.

Market prognosticators are spewing out opinions faster than the public can grasp, or understand. I choose to stick with basic fundamental value propositions and ignore the noise.

I have been buying for the past eight months and riding the market waves, good and bad, to huge gains -- so far. Maybe I will be giving some back, maybe not, but I have also been encouraging readers to take something off the table, in several recent posts.